Formulary Search Results for: LENALIDOMIDE
8.2.4 Other immunomodulating drugs - View Category
Total Formulary
LENALIDOMIDE (capsules)
Restrictions:
Formulary indications and restrictions on use are detailed in the Prescribing Notes below.
Prescribing Notes:
Muliple myeloma
For regional protocols click here [NHS network access required]
- Use for the third line treatment of multiple myeloma in combination with dexamethasone, or for patients who have received at least one prior therapy, is restricted in accordance with regional protocol.
- Adult patients with previously untreated multiple myeloma who are not eligible for transplant. It is restricted to specialist use in accordance with regional protocol for use in patients unsuitable for thalidomide-containing regimens.
- Use as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT) is restricted to use in accordance with regional protocol.
- Use in combination with dexamethsone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant, and are suitable for thalidomide-containing regimen (off-patent use)
Lymphoma
- In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 to 3a) is restricted to specialist use in accordance with regional protocol click here [NHS network access required].
Transfusion-dependent anaemia
Use for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate is restricted in accordance with regional protocol [NHS network access required].
Non-formulary indications:
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma is not recommended by SMC and remains non-formulary.
- As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.